After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa (Agencia Nacional de Vigilancia Sanitaria) has now decided to provisionally suspend the authorisation for exceptional import of 4 million doses of the Indian Covid-19 vaccine.
